General Prognostics (GPx), the company creating the world's first API for blood to digitize critical blood biomarkers and improve clinical predictions, today announces $3.25M in seed funding. Among the investors are D4V (Design for Ventures), a Tokyo-based venture capital firm in partnership with global design consultancy IDEO, as well as angel investors including Pete Moran, former long time General Partner at DCM Ventures, Hiroaki Kitano, Senior Executive Vice President and CTO at Sony Group Corporation and President & CEO at Sony Computer Science Laboratories, Inc., and Masao Hitotsuyanagi, former President of Terumo CardioVascular Company.

“Blood tests, surgically implanted devices and other monitoring methods used to track and treat serious ailments are often cumbersome, painful and expensive, which is why mortality and hospital re-admission rates are shockingly high for conditions like heart failure,” says Javier Echenique, CEO and co-founder of General Prognostics. “Our API for Blood platform improves patient outcomes by giving physicians the data they need to monitor critical blood biomarkers and make accurate predictions without invasive and costly procedures.”

Heart failure alone affects 6.2M adults in the US, resulting in hundreds of thousands of deaths a year and costs an estimated $30.7B per year. Even among patients treated in a hospital, 33% die or are re-hospitalized within 90 days because care strategies - including monitoring heart function - are ineffective due to lack of actionable data, patient burden or cost.

General Prognostics' ground-breaking platform opens the door to improving treatment and quality of life for those suffering from ailments starting with heart failure and including pulmonary arterial hypertension, hyperkalemia, and renal exacerbation.

At the heart of the platform is a powerful suite of AI algorithms, called the Canary Prediction Engine, that digitizes critical blood biomarkers to provide clinical predictions that, in the case of heart failure, are as accurate as surgically implanted devices.

The platform is part of a first-of-its-kind study, launched first at the University of Kansas Medical Center, evaluating at-home monitoring of heart failure patients to save lives while reducing healthcare costs and the need for invasive surgical procedures and painful blood tests.

”New human-centered approaches to accurately monitor patients' health can yield great benefits for global healthcare, especially among aging populations,” says Tom Kelley, Founder & Chairman at D4V. “General Prognostics gives doctors vital data to improve patient care and provides pharmaceutical partners new levels of insight that can accelerate clinical studies and commercialization efforts.”

About General Prognostics

General Prognostics is revolutionizing remote chronic disease management with the world's first “API for Blood.” Headquartered in Boston, GPx is a development-stage company dedicated to transforming the standard of care of cardiorenal diseases and enabling patients to better understand their condition, much like the continuous glucose monitor has transformed diabetes care. GPx was also in the Sony Startup Accelerator Program Europe 2021 batch and winner of the Boston Scientific Connected Patient Challenge VI. For information visit: gpx.ai

Media Contact
contact@generalprognostics.com

— WebWireID294738 —